1 / 10

CASE 1

CASE 1. Donald is a 68 year-old man who is admitted to hospital via the Emergency Department one day, following a myocardial infarction. Subsequent investigation reveals that his eGFR is 42 mL /min/1.73m2. He comes to see you after his discharge, to discuss his kidney problem. 

fadey
Download Presentation

CASE 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CASE 1

  2. Donald is a 68 year-old man who is admitted to hospital via the Emergency Department one day, following a myocardial infarction. Subsequent investigation reveals that his eGFR is 42 mL/min/1.73m2. He comes to see you after his discharge, to discuss his kidney problem.  Q.1 What stage of Chronic Kidney Disease (CKD) does this represent?

  3. Hence this represents stage 3 CKD • eGFRis estimated GFR and recommended to use MDRD (Modification of Diet in Renal Disease equation  more accurate than Cockcroft Gault among elderly and obese people and more accurate as kidney function declines) • MDRD also contains factors to be applied to African American subjects

  4. Q.2. What modifiable risk factors for CKD would you specifically seek in order to address them and slow progress to End Stage Renal Disease (ESRD)? • Smoking • Diabetes • HTN • Obesity • Also review medications. • Following drugs need to be reduced or ceased in people with CKD: • Colchicine (tubulin binding  for gout, as inhibits mitosis, neutrophil motility and activity) • Digoxin • Famciclovir • Gabapentin • Gibenclamide (sulfonylurea) • Glimepiride (sulfonylurea) • Lithium • Metformin • Sotalol • Valaciclovir • Triple whammy: NSAID/COX 2 inhibitor, ACE Inh, diuretic • Contrast • Aminoglycosides • Lithium

  5. ACE Inh and ARB slows progression of CKD esp in pt with proteinuria (stop if creatinine rises 30% of baseline) MOA: Reduced glomerular capillary hydraulic pressure in combination with diminished size- and charge-selective properties of the glomerular capillary membrane are the most likely mechanisms involved in the antiproteinuric effect of ACE inhibitors.

  6. Pt with CKD have substantial increase in cardiovascular risk that in part can be explained by increase in traditional risk factors such as HTN, diabetes, metabolic syndrome • CKD alone is also independent risk factor for cardiovascular disease • In CKD pt, risk of death is more due to cardiovascular disease (20 times greater) than requiring dialysis or transplantation • Q.3. Briefly outline the key points in the relationship between kidney and cardiovascular disease

  7. Goals: • Reduce progression of kidney disease • Reduce cardiovascular risk • Avoid & manage any complications • Any drugs that might damage kidney  avoid or adjust doses • Refer to Nephrologist when indicated Q.4. Briefly outline the key points in your clinical action plan for this man. • Monitoring: • 1 – 3 monthly clinical review, consisting: • Clinical Ax: • Blood pressure • Weight • Urine dipstick • Laboratory Ax: • Urea, creatinine, and electrolytes • eGFR • Fasting glucose • Fasting lipids • FBC • Iron stores • Ca and phosphate • PTH (quarterly) • Medications review

  8. Because CKD is silent condition but can be readily detected with tests for proteinuria, hematuria, and eGFR • Symptoms of CKD may not appear until kidney function is severely impaired • CKD is potent independent risk factor for cardiovascular disease • Early intervention can reduce CKD progression and cardiovascular risk by 50% and improves quality of life Q. 5. Why is it important to screen at-risk persons for CKD?

  9. Malnutrition  due to anorexia, decreased intestinal absorption and digestion and metabolic acidosis • Anorexia • Nausea • Vomitting • Fatigue • Sexual dysfunction • Platelet dysfunction (uremic bleeding) due to uremic toxins. Increased uremia also increase NO synthesis  inhibitor of platelet aggregation • Pericarditis • Neuropathy (including encephalopathy, sensory dysfunctions) Q. 6 What symptoms of uremia may occur in ESRD?

More Related